RAYNE ROUCE to Child
This is a "connection" page, showing publications RAYNE ROUCE has written about Child.
Connection Strength
0.344
-
EBV and post-transplant lymphoproliferative disorder: a complex relationship. Hematology Am Soc Hematol Educ Program. 2024 12 06; 2024(1):728-735.
Score: 0.058
-
Access offsets poverty in quest for CAR T cells. Blood. 2023 02 09; 141(6):558-560.
Score: 0.051
-
Reverse translational studies inform dual-targeted CAR T-cell design. Blood. 2022 08 04; 140(5):409-410.
Score: 0.050
-
The TGF-?/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 2016 Apr; 30(4):800-11.
Score: 0.031
-
Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults. Blood Adv. 2024 07 09; 8(13):3544-3548.
Score: 0.014
-
Enhancing pediatric access to cell and gene therapies. Nat Med. 2024 Jul; 30(7):1836-1846.
Score: 0.014
-
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
Score: 0.014
-
INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults. Transplant Cell Ther. 2024 Jun; 30(6):565-579.
Score: 0.014
-
Mediport use as an acceptable standard for CAR T cell infusion. Front Immunol. 2023; 14:1239132.
Score: 0.014
-
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2023 03 01; 108(3):747-760.
Score: 0.013
-
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
Score: 0.012
-
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. J Clin Oncol. 2022 03 20; 40(9):945-955.
Score: 0.012
-
Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. J Allergy Clin Immunol. 2022 02; 149(2):758-766.
Score: 0.012
-
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
Score: 0.010
-
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
Score: 0.009
-
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
Score: 0.009
-
Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy. Clin Cancer Res. 2013 Sep 15; 19(18):5079-91.
Score: 0.007